These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

72 related items for PubMed ID: 11370082

  • 1. [Aromatase inhibitors in the treatment of breast cancer].
    Ahokosk O, Salminen E.
    Duodecim; 1997; 113(5):401-5. PubMed ID: 11370082
    [No Abstract] [Full Text] [Related]

  • 2. Aromatase inhibitors for early breast cancer therapy: a choice of effective treatment strategies.
    Dixon JM, Bundred N.
    Eur J Surg Oncol; 2006 Mar; 32(2):123-5. PubMed ID: 16380226
    [No Abstract] [Full Text] [Related]

  • 3. [Aromatase inhibitors for metastasing breast cancer in postmenopausal women. A survey of a Cochrane review].
    Aziz M, Skougaard K, Kamby C, Nielsen DL.
    Ugeskr Laeger; 2008 Jun 16; 170(25):2248-52. PubMed ID: 18565316
    [No Abstract] [Full Text] [Related]

  • 4. Exemestane: new preparation. No tangible advance in metastatic breast cancer after tamoxifen failure.
    Prescrire Int; 2001 Aug 16; 10(54):108-9. PubMed ID: 11718178
    [Abstract] [Full Text] [Related]

  • 5. The biology of steroid hormones and endocrine treatment of breast cancer.
    Dowsett M, Folkerd E, Doody D, Haynes B.
    Breast; 2005 Dec 16; 14(6):452-7. PubMed ID: 16198110
    [Abstract] [Full Text] [Related]

  • 6. Endocrine therapy for early breast cancer.
    Hussain SA, Williams S, Stevens A, Rea DW.
    Expert Rev Anticancer Ther; 2004 Oct 16; 4(5):877-88. PubMed ID: 15485321
    [Abstract] [Full Text] [Related]

  • 7. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
    Singh Ranger G.
    J Clin Pharm Ther; 2005 Aug 16; 30(4):313-7. PubMed ID: 15985044
    [Abstract] [Full Text] [Related]

  • 8. Definition of postmenopausal status, age of the breast cancer patients and the outcome of aromatase inhibitors treatment.
    Aksoy S, Dizdar O, Altundag K.
    Breast; 2008 Oct 16; 17(5):433-5. PubMed ID: 18565752
    [No Abstract] [Full Text] [Related]

  • 9. Latest studies hint at survival advantage with aromatase inhibitors in early breast cancer.
    Tuma RS.
    J Natl Cancer Inst; 2006 Jan 18; 98(2):86-7. PubMed ID: 16418506
    [No Abstract] [Full Text] [Related]

  • 10. The similarities of aromatase inhibitors outweigh the differences.
    Jänicke F.
    Anticancer Drugs; 2008 Mar 18; 19 Suppl 2():S7-9. PubMed ID: 18337642
    [Abstract] [Full Text] [Related]

  • 11. Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients.
    Bria E, Ciccarese M, Giannarelli D, Cuppone F, Nisticò C, Nuzzo C, Natoli G, Fabi A, Terzoli E, Cognetti F, Carlini P.
    Cancer Treat Rev; 2006 Aug 18; 32(5):325-32. PubMed ID: 16766125
    [Abstract] [Full Text] [Related]

  • 12. Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?
    Biganzoli L, Licitra S, Claudino W, Pestrin M, Leo AD.
    Eur J Cancer; 2007 Oct 18; 43(15):2270-8. PubMed ID: 17698345
    [Abstract] [Full Text] [Related]

  • 13. [Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
    Bruntsch U.
    MMW Fortschr Med; 2002 Sep 19; 144(38):20. PubMed ID: 12395697
    [No Abstract] [Full Text] [Related]

  • 14. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
    Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR.
    J Clin Oncol; 2005 Jan 20; 23(3):619-29. PubMed ID: 15545664
    [Abstract] [Full Text] [Related]

  • 15. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
    Dixon JM.
    Expert Rev Anticancer Ther; 2008 Mar 20; 8(3):453-63. PubMed ID: 18366292
    [Abstract] [Full Text] [Related]

  • 16. Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice.
    Sánchez-Muñoz A, Ribelles N, Márquez A, Pérez-Ruiz E, Alba E.
    J Clin Oncol; 2009 Dec 10; 27(35):e255-6; author reply e257-8. PubMed ID: 19884520
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.
    Buzdar AU, Vergote I, Sainsbury R.
    Breast J; 2004 Dec 10; 10(3):211-7. PubMed ID: 15125747
    [Abstract] [Full Text] [Related]

  • 20. [Aromatase inhibitors in the adjuvant therapy of breast cancer].
    Bauerschlag D, Schem C, Maass N, Jonat W.
    Gynakol Geburtshilfliche Rundsch; 2005 Jun 10; 45(3):132-6. PubMed ID: 15990437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.